Some of the targets for chondrosarcoma therapies involve mutations of isocitrate dehydrogenases IDH1 and IDH2 [37,38,39,40], angiogenesis [41,42], cyclin-dependent kinases (CDK) [43], tyrosine kinase inhibitor [44], mechanisms involved in the signaling pathway of Rapamycin (mTOR) [45,46], agents of hypomethylation, and histone deacetylase (HDAC) [47,48,49]. This evidence concerns the gene IDH2 and chondrosarcoma.